The polymorphic oxidation of beta-adrenoceptor antagonists. Clinical pharmacokinetic considerations (Q39422300)

11 September 2017

1 reference

title

The polymorphic oxidation of beta-adrenoceptor antagonists. Clinical pharmacokinetic considerations (English)

1 reference

11 September 2017

1 reference

Lennard MS

1

1 reference

11 September 2017

Tucker GT

series ordinal

2

1 reference

11 September 2017

Woods HF

series ordinal

3

1 reference

11 September 2017

1 January 1986

1 reference

Clinical Pharmacokinetics

11 September 2017

1 reference

11 September 2017

11

1 reference

11 September 2017

1-17

1 reference

11 September 2017

1

1 reference

https://scigraph.springernature.com/pub.10.2165/00003088-198611010-00001

11 September 2017

0 references

cites work

Genetically determined variability in acetylation and oxidation. Therapeutic implications

1 reference

12 December 2020

Debrisoquine-type polymorphism of drug oxidation: purification from human liver of a cytochrome P450 isozyme with high activity for bufuralol hydroxylation

1 reference

12 December 2020

Defective N-oxidation of sparteine in man: A new pharmacogenetic defect

1 reference

12 December 2020

The relationship between debrisoquine oxidation phenotype and the pharmacokinetics and pharmacodynamics of propranolol

1 reference

12 December 2020

Treatment of hypertension with beta-adrenoceptor blocking drugs

1 reference

12 December 2020

Timolol and atenolol: relationships between oxidation phenotype, pharmacokinetics and pharmacodynamics

1 reference

12 December 2020

The effect of impaired renal function on the plasma concentration and urinary excretion of metoprolol metabolites

1 reference

12 December 2020

Bufuralol metabolism in human liver: a sensitive probe for the debrisoquine-type polymorphism of drug oxidation

1 reference

12 December 2020

The genetic controlof bufuralol metabolisminman

1 reference

12 December 2020

Genetic polymorphism in drug oxidation: in vitro studies of human debrisoquine 4-hydroxylase and bufuralol 1'-hydroxylase activities

1 reference

12 December 2020

Pharmacokinetics of two beta blocking drugs: detection of a pharmacogenetic abnormality

1 reference

12 December 2020

Metoprolol and debrisoquin metabolism in Nigerians: lack of evidence for polymorphic oxidation

1 reference

12 December 2020

Polymorphic hydroxylation of debrisoquine

1 reference

12 December 2020

High plasma concentrations of beta-receptor blocking drugs and deficient debrisoquine hydroxylation

1 reference

12 December 2020

Polymorphic ability to metabolize propranolol alters 4-hydroxypropranolol levels but not beta blockade

1 reference

12 December 2020

Ethnic differences in drug metabolism

1 reference

12 December 2020

Physiological disposition and metabolism of timolol in man and laboratory animals

1 reference

12 December 2020

Beta-adrenoceptor blocking drugs: Adverse reactions and drug interactions

1 reference

12 December 2020

Impaired oxidation of debrisoquine in patients with perhexiline neuropathy

1 reference

12 December 2020

Defective oxidation of drugs: pharmacokinetic and therapeutic implications

1 reference

12 December 2020

Metabolism of metoprolol in the rat in vitro and in vivo

1 reference

12 December 2020

Effects of beta-adrenoceptor antagonists on the pharmacokinetics of lignocaine

1 reference

12 December 2020

Effect of route of administration on the relationship between -adrenergic blockade and plasma propranolol level.

1 reference

12 December 2020

Hepatic monooxygenase activities in subjects with a genetic defect in drug oxidation.

1 reference

12 December 2020

Lack of evidence for polymorphism in metoprolol metabolism

1 reference

12 December 2020

Proximal myopathy during beta-blockade

1 reference

12 December 2020

Effect of oxidative polymorphism (debrisoquine/sparteine type) on hepatic first-pass metabolism of bufuralol

1 reference

12 December 2020

Plasma levels and pharmacological effects of metoprolol administered as controlled release (Durules) and ordinary tablets in healthy volunteers

1 reference

12 December 2020

Plasma levels of (+) and (-)-propranolol and 4-hydroxypropranolol after administration of racemic (+/-)-propranolol in man

1 reference

12 December 2020

Pharmacogenetic covariation of defective N-oxidation of sparteine and 4-hydroxylation of debrisoquine

1 reference

12 December 2020

Assay and characterisation of debrisoquine 4-hydroxylase activity of microsomal fractions of human liver

1 reference

12 December 2020

Interaction of phenobarbital with propranolol in the dog. 3. Beta blockade

1 reference

12 December 2020

Oxidation phenotype--a major determinant of metoprolol metabolism and response

1 reference

12 December 2020

Pharmacokinetic studies on the selective beta1-receptor antagonist metoprolol in man.

1 reference

12 December 2020

Competitive inhibition of sparteine oxidation in human liver by β-adrenoceptor antagonists and other cardiovascular drugs

1 reference

12 December 2020

Inter-ethnic difference in sparteine oxidation among Ghanaians and Germans

1 reference

12 December 2020

Simultaneous determination of metoprolol and metabolites in urine by capillary column gas chromatography as oxazolidineone and trimethylsilyl derivatives

1 reference

12 December 2020

Variability of plasma drug concentrations: some observations

1 reference

12 December 2020

The disposition of debrisoquine in hypertensive patients

1 reference

12 December 2020

A human cytochrome P-450 characterized by inhibition studies as the sparteine-debrisoquine monooxygenase

1 reference

12 December 2020

Characterization of a common genetic defect of cytochrome P-450 function (debrisoquine-sparteine type polymorphism)--increased Michaelis is Constant (Km) and loss of stereoselectivity of bufuralol 1'-hydroxylation in poor metabolizers

1 reference

12 December 2020

Urinary metabolites of timolol from humans and laboratory animals. Syntheses and beta-adrenergic blocking activities

1 reference

12 December 2020

Effects of metoprolol and propranolol on theophylline elimination

1 reference

12 December 2020

A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.

1 reference

12 December 2020

Interindividual variation of beta-adrenoceptor blocking drugs, plasma concentration and effect: influence of genetic status on behaviour of atenolol, bopindolol and metoprolol

1 reference

12 December 2020

Clinical pharmacokinetics of metoprolol

1 reference

12 December 2020

Metabolism of metoprolol-(3-h) in man, the dog and the rat

1 reference

12 December 2020

Clinical Pharmacokinetics of β-Adrenoreceptor Blocking Drugs

1 reference

12 December 2020

Debrisoquine polymorphism and the metabolism and action of metoprolol, timolol, propranolol and atenolol

1 reference

12 December 2020

Respiratory effects of timolol

1 reference

12 December 2020

Pharmacokinetic and clinical consequences of the genetic polymorphism of oxidation

1 reference

12 December 2020

Differential stereoselective metabolism of metoprolol in extensive and poor debrisoquin metabolizers

1 reference

12 December 2020

Polymorphic hydroxylation of Debrisoquine in man.

1 reference

12 December 2020

Inhibition of antipyrine metabolism by beta-adrenoceptor antagonists

1 reference

12 December 2020

Comparison of two slow-release formulations of metoprolol with conventional metoprolol and atenolol in hypertensive patients

1 reference

12 December 2020

Deficient metabolism of debrisoquine and sparteine

1 reference

12 December 2020

Adverse effects from metoprolol are not generally associated with oxidation status

1 reference

12 December 2020

Contribution of the genetic status of oxidative metabolism to variability in the plasma concentrations of beta-adrenoceptor blocking agents

1 reference

12 December 2020

Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism

1 reference

12 December 2020

Quantitative account of propranolol metabolism in urine of normal man.

1 reference

12 December 2020

Characterization of a human liver cytochrome P-450 involved in the oxidation of debrisoquine and other drugs by using antibodies raised to the analogous rat enzyme

1 reference

12 December 2020

Plasma levels and β-blocking effect of α-hydroxymetoprolol—Metabolite of metoprolol—in the dog

1 reference

12 December 2020

A study of the debrisoquine hydroxylation polymorphism in a Nigerian population

1 reference

12 December 2020

Defective hydroxylation of bufuralol associated with side-effects of the drug in poor metabolisers [letter]

1 reference

12 December 2020

Defective metabolism of metoprolol in poor hydroxylators of debrisoquine

1 reference

12 December 2020

Pharmacokinetics and beta-blocking effects of timolol in poor and extensive metabolizers of debrisoquin

1 reference

12 December 2020

Oxidation phenotype and the metabolism and action of beta-blockers

1 reference

12 December 2020

Comparison of two long-acting preparations of metoprolol with conventional metoprolol and atenolol in healthy men during chronic dosing

1 reference

12 December 2020

Metoprolol pharmacokinetics and the oral contraceptive pill

1 reference

12 December 2020

Influence of renal failure on the hepatic clearance of bufuralol in man

1 reference

12 December 2020

Determined of bufuralol and its metabolites in plasma by mass fragmentography and by gas chromatography with electron capture detection

1 reference

12 December 2020

Evidence for an enzymatic defect in the 4-hydroxylation of debrisoquine by human liver

1 reference

12 December 2020

Interindividual variations in metoprolol metabolism--some clinical and other observations

1 reference

12 December 2020

Plasma propranolol levels in the quaniitative assessment of beta-adrenergic blockade in man

1 reference

12 December 2020

Metoprolol metabolism and debrisoquine oxidation polymorphism--population and family studies

1 reference

12 December 2020

Substrate specificity of the form of cytochrome P-450 catalyzing the 4-hydroxylation of debrisoquine in man

1 reference

12 December 2020

Oxidation polymorphism has clinical relevance

1 reference

12 December 2020

Pharmacokinetics of metoprolol and its metabolite alpha-OH-metoprolol in healthy, non-smoking, elderly individuals

1 reference

12 December 2020

10.2165/00003088-198611010-00001

Identifiers

DOI

1 reference

Dimensions Publication ID

11 September 2017

0 references

1 reference